Kayexalate Drug Interactions Require More Studies: FDA

Federal regulators are ordering the manufacturer of the generic drug Kayexalate, a potassium decreasing medication, to conduct new clinical studies to ensure that it does not alter or bind to other medications, potentially decreasing the effects of other drugs. 

In a drug safety communication on October 22, the FDA announced that the manufacturer of Kayexalate, Concordia Pharmaceuticals, will conduct further studies to determine if the medication can bind and alter the effect of other oral medications.

Kayexalate is classified as a sodium polystyrene sulfonate and is used to treat patients with high levels of potassium in their blood. The prescription medication is taken orally usually between one and four times per day to allow the body to bind potassium in the large intestine so it can be removed naturally. High levels of potassium in the blood can cause heart rhythm issues.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

The FDA demanded the new studies after research found a similar sodium polystyrene sulfonate potassium-lowering drug, Veltassa, altered other medications’ efficacy. The researchers found that Veltassa bound to about half of the prescription medications it was tested with, including prescription blood pressure and blood thinners, and also over-the-counter drugs.

As a result, Valtassa’s manufacturer was forced to change the warning label on the medication to instruct users to not take any other forms of oral medication within six hours of it to avoid disruptions.

The FDA stated that the binding of medications could cause serious adverse health consequences in users, potentially decreasing the effects of other medications. Such interferences could exacerbate and individuals pre-existing heart condition since high potassium levels are known to cause heart rhythm problems.

If the additional studies into Kayexalate result in similar findings showing medication binding, the FDA will require Concordia and all other sodium polystyrene sulfonate manufacturers to update their label warnings as well.

Until the studies are complete, the FDA recommends that Kayexalate patients avoid taking any other oral medications within six hours of their Kayexalate dose. Individuals are not being instructed to stop taking their potassium lowering medications nor any other form of prescribed or over-the-counter medication and should consult with their healthcare provider for further instructions regarding dosage separation.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024
Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024 (Posted yesterday)

With thousands of Bard hernia mesh lawsuits pending in the federal court system, a fourth bellwether trial will be held in the spring, involving allegations that defects with Bard 3DMax caused painful and permanent injuries.

Ozempic Gastroparesis Lawsuit Filed Over Failure To Warn About Permanent Stomach Problems
Ozempic Gastroparesis Lawsuit Filed Over Failure To Warn About Permanent Stomach Problems (Posted 3 days ago)

A South Dakota man has filed one of the first gastroparesis lawsuits against Ozempic manufacturers, alleging that users have not been adequately warned about the risk of severe vomiting and long-term stomach side effects.